Premium
Cytosine arabinoside (Ara‐C) plus alpha‐interferon (αIFN) determine prolonged complete remissions in patients with aggressive non‐Hodgkin's lymphoma partially responsive to first‐line doxorubicin‐containing regimens
Author(s) -
Palmieri Giovannella,
Morabito Alessandro,
Rea Antonio,
Caraglia Michele,
Tafliaferri Pierosandro,
Bianco Angelo Raffaele
Publication year - 1994
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1994.tb05046.x
Subject(s) - medicine , lymphoma , chemotherapy , gastroenterology , alpha interferon , doxorubicin , toxicity , complete remission , cytarabine , interferon , immunology
Summary. Ten patients with aggressive NHL who failed to achieve a complete remission with first‐line chemotherapy were treated with Ara‐C and αIFN. Ara‐C was administered subcutaneously at 100mg on day 1, 150mg on day 2 and 200 mg on days 3,4 and 5 of a 28 d cycle; αIFN was given at 3 million International Units three times a week and continued for 2 years in CR patients. Six CR were attained with a median duration of 36+ months. Toxicity was mild. A new approach to second‐line therapy for aggressive NHL is proposed.